The estimated Net Worth of Tracey Haas Wielinski is at least $5.87 Миллион dollars as of 6 March 2014. Tracey Wielinski owns over 8,275 units of Insulet stock worth over $5,465,520 and over the last 11 years Tracey sold PODD stock worth over $407,213.
Tracey has made over 1 trades of the Insulet stock since 2014, according to the Form 4 filled with the SEC. Most recently Tracey sold 8,275 units of PODD stock worth $407,213 on 6 March 2014.
The largest trade Tracey's ever made was selling 8,275 units of Insulet stock on 6 March 2014 worth over $407,213. On average, Tracey trades about 4,138 units every 0 days since 2014. As of 6 March 2014 Tracey still owns at least 24,000 units of Insulet stock.
You can see the complete history of Tracey Wielinski stock trades at the bottom of the page.
Tracey's mailing address filed with the SEC is C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD, MA, 01730.
Over the last 18 years, insiders at Insulet have traded over $64,849,299 worth of Insulet stock and bought 175,262 units worth $7,280,516 . The most active insiders traders include Jonathan Silverstein, Elizabeth H Weatherman и Samuel D Colella. On average, Insulet executives and independent directors trade stock every 19 days with the average trade being worth of $2,473,148. The most recent stock trade was executed by Timothy J Scannell on 10 September 2024, trading 5,000 units of PODD stock currently worth $1,129,200.
insulet corporation is an innovative medical device company based in billerica, massachusetts. it was founded in 2000 with the mission of improving the lives of people with diabetes. specifically, through its revolutionary omnipod insulin management system, insulet seeks to expand the use of insulin pump therapy. studies have demonstrated the advantages of insulin pump therapy over multiple daily insulin injections (mdi); these advantages include better glycemic control, fewer hypoglycemic events, reduced glycemic variability1 and improved quality of life2. despite these benefits, most people still choose mdi therapy largely due to the complexity, cost and inconvenience of conventional pump technology. the omnipod is a discreet and easy-to-use system that eliminates many of the issues associated with conventional pumps. improvements include omnipod's lack of tubing; automated, virtually pain-free insertion; and two straightforward parts that communicate wirelessly. by breaking down
Insulet executives and other stock owners filed with the SEC include: